Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 12Colonic Neoplasms 11Neoplasm Metastasis 9Head and Neck Neoplasms 8Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Squamous Cell 2mCRC 1Stomach Neoplasms 1Skin Neoplasms 1Recurrence 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Metastasis Colon Cancer 1Incurable Colorectal Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1

Interventions

S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mCRC × Cetuximab × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡